We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
34 result(s) found, displaying 21 to 30
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Teriparatide
-
Prescription medicine decision summaryTGA decision: TERROSA (teriparatide) is approved to treat osteoporosis in postmenopausal women and primary osteoporosis in men.
-
Prescription medicine decision summaryTGA decision: Reagila (cariprazine hydrochloride) is approved to treat schizophrenia in adult patients.
-
Prescription medicine registrationActive ingredients: teriparatide.
-
Prescription medicine registrationActive ingredients: cariprazine hydrochloride.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEMFOLA follitropin alfa (rch) 75 IU/0.125 mL (5.5 microgram) solution for injection cartridge in a pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEMFOLA follitropin alfa (rch) 150 IU/0.25 mL (11 microgram) solution for injection cartridge in a pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEMFOLA follitropin alfa (rch) 450 IU/0.75 mL (33 microgram) solution for injection cartridge in a pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEMFOLA follitropin alfa (rch) 225 IU/0.375 mL (16.5 microgram) solution for injection cartridge in a pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AFOLIA follitropin alfa (rch) 75 IU/0.125 mL (5.5 microgram) solution for injection cartridge in a pre-filled pen.